BioPharma
Regeneron Looks to Infusing More Funds into Gene Editing
Regeneron Pharmaceuticals is going ahead and investing more funds into gene editing, as it has announced a collaboration with Tessera Therapeutics in December 2025, so as to create an experimental program pertaining to rare liver and lung disease.
At the...
BioPharma
Trump To Exempt UK-Origin Pharmaceuticals from Tariffs
The Trump administration has lined up yet another country-specific trade agreement, and this time it is going to be with the U.K., which confers the biggest break on pharmaceutical import tariffs yet with Washington.
For its part, the U.K., which...
BioPharma
Transforming Clinical Trials Automation and Sustainability
In a time of fast technological change and rising environmental awareness, the pharmaceutical industry is looking for new ways to stay ahead. Because of this work, automation has been found to be a very useful tool for changing the...
BioPharma
Azerbaijan, Jordan Explore Joint Pharmaceutical Venture
Azerbaijan and Jordan are looking out for new opportunities in order to establish a joint pharmaceutical venture, thereby signalling a very robust step towards much deeper economic cooperation.
As per Azernews, this occurrence was highlighted by Yarub Al-Guda, the Jordanian...
BioPharma
India, Switzerland Discuss Pharma and Biotech Collaboration
Piyush Goyal, the Commerce and Industry Minister, met Helene Budliger Artieda, the visiting Swiss State Secretary for Economic Affairs, and discussed cooperation when it comes to research and development as well as pharma and biotech collaboration with a view...
BioPharma
Algeria Showcases its Strength in African Pharma Sector
Abdelmadjid Tebboune, the Algerian president, went on to address participants at the African Ministerial Conference on Local Pharmaceutical Production and Health Technologies on November 27, 2025, with his message being read by Sifi Ghrieb, the prime minister.
The event, which...
BioPharma
Eli Lilly Becomes the First Drugmaker to Hit $1tn Valuation
Eli Lilly, the US pharma giant, has become the first drugmaker to hit $1tn valuation on November 22, 2025, hence entering the exclusive club, which is so far dominated by technology giants, highlighting its rise as a weight-loss powerhouse.
The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.